Cargando…

Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin

Recent data suggest that olfactory deficits could represent an early marker and a pathogenic mechanism at the basis of cognitive decline in type 2 diabetes (T2D). However, research is needed to further characterize olfactory deficits in diabetes, their relation to cognitive decline and underlying me...

Descripción completa

Detalles Bibliográficos
Autores principales: Lietzau, Grazyna, Davidsson, William, Östenson, Claes-Göran, Chiazza, Fausto, Nathanson, David, Pintana, Hiranya, Skogsberg, Josefin, Klein, Thomas, Nyström, Thomas, Darsalia, Vladimer, Patrone, Cesare
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824492/
https://www.ncbi.nlm.nih.gov/pubmed/29471869
http://dx.doi.org/10.1186/s40478-018-0517-1
_version_ 1783302035436732416
author Lietzau, Grazyna
Davidsson, William
Östenson, Claes-Göran
Chiazza, Fausto
Nathanson, David
Pintana, Hiranya
Skogsberg, Josefin
Klein, Thomas
Nyström, Thomas
Darsalia, Vladimer
Patrone, Cesare
author_facet Lietzau, Grazyna
Davidsson, William
Östenson, Claes-Göran
Chiazza, Fausto
Nathanson, David
Pintana, Hiranya
Skogsberg, Josefin
Klein, Thomas
Nyström, Thomas
Darsalia, Vladimer
Patrone, Cesare
author_sort Lietzau, Grazyna
collection PubMed
description Recent data suggest that olfactory deficits could represent an early marker and a pathogenic mechanism at the basis of cognitive decline in type 2 diabetes (T2D). However, research is needed to further characterize olfactory deficits in diabetes, their relation to cognitive decline and underlying mechanisms. The aim of this study was to determine whether T2D impairs odour detection, olfactory memory as well as neuroplasticity in two major brain areas responsible for olfaction and odour coding: the main olfactory bulb (MOB) and the piriform cortex (PC), respectively. Dipeptidyl peptidase-4 inhibitors (DPP-4i) are clinically used T2D drugs exerting also beneficial effects in the brain. Therefore, we aimed to determine whether DPP-4i could reverse the potentially detrimental effects of T2D on the olfactory system. Non-diabetic Wistar and T2D Goto-Kakizaki rats, untreated or treated for 16 weeks with the DPP-4i linagliptin, were employed. Odour detection and olfactory memory were assessed by using the block, the habituation-dishabituation and the buried pellet tests. We assessed neuroplasticity in the MOB by quantifying adult neurogenesis and GABAergic inhibitory interneurons positive for calbindin, parvalbumin and carletinin. In the PC, neuroplasticity was assessed by quantifying the same populations of interneurons and a newly identified form of olfactory neuroplasticity mediated by post-mitotic doublecortin (DCX) + immature neurons. We show that T2D dramatically reduced odour detection and olfactory memory. Moreover, T2D decreased neurogenesis in the MOB, impaired the differentiation of DCX+ immature neurons in the PC and altered GABAergic interneurons protein expression in both olfactory areas. DPP-4i did not improve odour detection and olfactory memory. However, it normalized T2D-induced effects on neuroplasticity. The results provide new knowledge on the detrimental effects of T2D on the olfactory system. This knowledge could constitute essentials for understanding the interplay between T2D and cognitive decline and for designing effective preventive therapies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40478-018-0517-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5824492
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58244922018-02-26 Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin Lietzau, Grazyna Davidsson, William Östenson, Claes-Göran Chiazza, Fausto Nathanson, David Pintana, Hiranya Skogsberg, Josefin Klein, Thomas Nyström, Thomas Darsalia, Vladimer Patrone, Cesare Acta Neuropathol Commun Research Recent data suggest that olfactory deficits could represent an early marker and a pathogenic mechanism at the basis of cognitive decline in type 2 diabetes (T2D). However, research is needed to further characterize olfactory deficits in diabetes, their relation to cognitive decline and underlying mechanisms. The aim of this study was to determine whether T2D impairs odour detection, olfactory memory as well as neuroplasticity in two major brain areas responsible for olfaction and odour coding: the main olfactory bulb (MOB) and the piriform cortex (PC), respectively. Dipeptidyl peptidase-4 inhibitors (DPP-4i) are clinically used T2D drugs exerting also beneficial effects in the brain. Therefore, we aimed to determine whether DPP-4i could reverse the potentially detrimental effects of T2D on the olfactory system. Non-diabetic Wistar and T2D Goto-Kakizaki rats, untreated or treated for 16 weeks with the DPP-4i linagliptin, were employed. Odour detection and olfactory memory were assessed by using the block, the habituation-dishabituation and the buried pellet tests. We assessed neuroplasticity in the MOB by quantifying adult neurogenesis and GABAergic inhibitory interneurons positive for calbindin, parvalbumin and carletinin. In the PC, neuroplasticity was assessed by quantifying the same populations of interneurons and a newly identified form of olfactory neuroplasticity mediated by post-mitotic doublecortin (DCX) + immature neurons. We show that T2D dramatically reduced odour detection and olfactory memory. Moreover, T2D decreased neurogenesis in the MOB, impaired the differentiation of DCX+ immature neurons in the PC and altered GABAergic interneurons protein expression in both olfactory areas. DPP-4i did not improve odour detection and olfactory memory. However, it normalized T2D-induced effects on neuroplasticity. The results provide new knowledge on the detrimental effects of T2D on the olfactory system. This knowledge could constitute essentials for understanding the interplay between T2D and cognitive decline and for designing effective preventive therapies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40478-018-0517-1) contains supplementary material, which is available to authorized users. BioMed Central 2018-02-23 /pmc/articles/PMC5824492/ /pubmed/29471869 http://dx.doi.org/10.1186/s40478-018-0517-1 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Lietzau, Grazyna
Davidsson, William
Östenson, Claes-Göran
Chiazza, Fausto
Nathanson, David
Pintana, Hiranya
Skogsberg, Josefin
Klein, Thomas
Nyström, Thomas
Darsalia, Vladimer
Patrone, Cesare
Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin
title Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin
title_full Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin
title_fullStr Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin
title_full_unstemmed Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin
title_short Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin
title_sort type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the dpp-4 inhibitor linagliptin
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824492/
https://www.ncbi.nlm.nih.gov/pubmed/29471869
http://dx.doi.org/10.1186/s40478-018-0517-1
work_keys_str_mv AT lietzaugrazyna type2diabetesimpairsodourdetectionolfactorymemoryandolfactoryneuroplasticityeffectspartlyreversedbythedpp4inhibitorlinagliptin
AT davidssonwilliam type2diabetesimpairsodourdetectionolfactorymemoryandolfactoryneuroplasticityeffectspartlyreversedbythedpp4inhibitorlinagliptin
AT ostensonclaesgoran type2diabetesimpairsodourdetectionolfactorymemoryandolfactoryneuroplasticityeffectspartlyreversedbythedpp4inhibitorlinagliptin
AT chiazzafausto type2diabetesimpairsodourdetectionolfactorymemoryandolfactoryneuroplasticityeffectspartlyreversedbythedpp4inhibitorlinagliptin
AT nathansondavid type2diabetesimpairsodourdetectionolfactorymemoryandolfactoryneuroplasticityeffectspartlyreversedbythedpp4inhibitorlinagliptin
AT pintanahiranya type2diabetesimpairsodourdetectionolfactorymemoryandolfactoryneuroplasticityeffectspartlyreversedbythedpp4inhibitorlinagliptin
AT skogsbergjosefin type2diabetesimpairsodourdetectionolfactorymemoryandolfactoryneuroplasticityeffectspartlyreversedbythedpp4inhibitorlinagliptin
AT kleinthomas type2diabetesimpairsodourdetectionolfactorymemoryandolfactoryneuroplasticityeffectspartlyreversedbythedpp4inhibitorlinagliptin
AT nystromthomas type2diabetesimpairsodourdetectionolfactorymemoryandolfactoryneuroplasticityeffectspartlyreversedbythedpp4inhibitorlinagliptin
AT darsaliavladimer type2diabetesimpairsodourdetectionolfactorymemoryandolfactoryneuroplasticityeffectspartlyreversedbythedpp4inhibitorlinagliptin
AT patronecesare type2diabetesimpairsodourdetectionolfactorymemoryandolfactoryneuroplasticityeffectspartlyreversedbythedpp4inhibitorlinagliptin